NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 57 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2016. The put-call ratio across all filers is 6.52 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $5,000 | -54.5% | 47,698 | +2.1% | 0.00% | – |
| Q3 2018 | $11,000 | 0.0% | 46,701 | +54.8% | 0.00% | – |
| Q1 2018 | $11,000 | -67.6% | 30,165 | -68.6% | 0.00% | – |
| Q4 2017 | $34,000 | -58.0% | 95,985 | -50.9% | 0.00% | – |
| Q3 2017 | $81,000 | +6.6% | 195,631 | +31.5% | 0.00% | – |
| Q2 2017 | $76,000 | +153.3% | 148,764 | +182.7% | 0.00% | – |
| Q1 2017 | $30,000 | +150.0% | 52,624 | +185.7% | 0.00% | – |
| Q4 2016 | $12,000 | -78.9% | 18,421 | -70.4% | 0.00% | – |
| Q3 2016 | $57,000 | -51.7% | 62,175 | -72.1% | 0.00% | -100.0% |
| Q2 2016 | $118,000 | -15.7% | 222,880 | +50.9% | 0.00% | 0.0% |
| Q1 2016 | $140,000 | -48.1% | 147,749 | -27.2% | 0.00% | -50.0% |
| Q4 2015 | $270,000 | -80.7% | 202,967 | -66.9% | 0.00% | -77.8% |
| Q3 2015 | $1,399,000 | +3008.9% | 613,402 | +2466.1% | 0.01% | – |
| Q4 2014 | $45,000 | +7.1% | 23,904 | -15.0% | 0.00% | -100.0% |
| Q2 2014 | $42,000 | – | 28,119 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
| Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
| DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
| STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
| Hudock, Inc. | 30,500 | $63,000 | 0.05% |
| BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
| TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
| NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
| BOLTON LP | 77,400 | $160,000 | 0.03% |